Amy Dyken, controller at Ayayai Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Ayayai's financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Ayayai Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% $1,020,000 7% convertible bonds payable 4,970,000 10% bonds payable 5,980,000 Total long-term debt $11,970,000 Shareholders' equity Preferred stock, 5% cumulative, $50 par value, 95,000 shares authorized, 23,750 shares issued and outstanding $1,187,500 Common stock, $1 par, 9,900,000 shares authorized, 990,000 shares issued and outstanding 990,000 Additional paid-in capital 4,050,000 Retained earnings 5,900,000 Total shareholders' equity $12,127,500
Reporting Cash Flows
Reporting of cash flows means a statement of cash flow which is a financial statement. A cash flow statement is prepared by gathering all the data regarding inflows and outflows of a company. The cash flow statement includes cash inflows and outflows from various activities such as operating, financing, and investment. Reporting this statement is important because it is the main financial statement of the company.
Balance Sheet
A balance sheet is an integral part of the set of financial statements of an organization that reports the assets, liabilities, equity (shareholding) capital, other short and long-term debts, along with other related items. A balance sheet is one of the most critical measures of the financial performance and position of the company, and as the name suggests, the statement must balance the assets against the liabilities and equity. The assets are what the company owns, and the liabilities represent what the company owes. Equity represents the amount invested in the business, either by the promoters of the company or by external shareholders. The total assets must match total liabilities plus equity.
Financial Statements
Financial statements are written records of an organization which provide a true and real picture of business activities. It shows the financial position and the operating performance of the company. It is prepared at the end of every financial cycle. It includes three main components that are balance sheet, income statement and cash flow statement.
Owner's Capital
Before we begin to understand what Owner’s capital is and what Equity financing is to an organization, it is important to understand some basic accounting terminologies. A double-entry bookkeeping system Normal account balances are those which are expected to have either a debit balance or a credit balance, depending on the nature of the account. An asset account will have a debit balance as normal balance because an asset is a debit account. Similarly, a liability account will have the normal balance as a credit balance because it is amount owed, representing a credit account. Equity is also said to have a credit balance as its normal balance. However, sometimes the normal balances may be reversed, often due to incorrect journal or posting entries or other accounting/ clerical errors.
![Amy Dyken, controller at Ayayai Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and
diluted earnings per share and the related disclosure for Ayayai's financial statements. Below is selected financial information for the
fiscal year ended June 30, 2020.
Ayayai Pharmaceutical Industries
Selected Balance Sheet Information
June 30, 2020
Long-term debt
Notes payable, 10%
$1,020,000
7% convertible bonds payable
4,970,000
10% bonds payable
5,980,000
Total long-term debt
$11,970,000
Shareholders' equity
Preferred stock, 5% cumulative, $50 par value, 95,000 shares authorized, 23,750 shares issued and outstanding
$1,187,500
Common stock, $1 par, 9,900,000 shares authorized, 990,000 shares issued and outstanding
990,000
Additional paid-in capital
4,050,000
Retained earnings
5,900,000
Total shareholders' equity
$12,127,500](/v2/_next/image?url=https%3A%2F%2Fcontent.bartleby.com%2Fqna-images%2Fquestion%2F195bb005-d4df-48e4-b413-b8a80fbd65f6%2Fd8f1a594-e73e-4de6-b2f7-48dc46ec39f9%2Fbccrba_processed.png&w=3840&q=75)
![Options were granted on July 1, 2019, to purchase 220,000 shares at $14 per share. Although no options were exercised
during fiscal year 2020, the average price per common share during fiscal year 2020 was $20 per share.
1.
Each bond was issued at face value. The 7% convertible bonds will convert into common stock at 50 shares per $1,000 bond.
The bonds are exercisable after 5 years and were issued in fiscal year 2019.
2.
3.
The preferred stock was issued in 2019.
4.
There are no preferred dividends in arrears; however, preferred dividends were not declared in fiscal year 2020.
5.
The 990,000 shares of common stock were outstanding for the entire 2020 fiscal year.
6.
Net income for fiscal year 2020 was $1,520,000, and the average income tax rate is 20%.
For the fiscal year ended June 30, 2020, calculate the following for Ayayai Pharmaceutical Industries. (Round answers to 2 decimal
places, e.g. $2.45.)
(a) Basic earnings per share.
Basic earnings per share
$
(b) Diluted earnings per share.
Diluted earnings per share
$
%24
%24](/v2/_next/image?url=https%3A%2F%2Fcontent.bartleby.com%2Fqna-images%2Fquestion%2F195bb005-d4df-48e4-b413-b8a80fbd65f6%2Fd8f1a594-e73e-4de6-b2f7-48dc46ec39f9%2Fi3xlv5_processed.png&w=3840&q=75)
![](/static/compass_v2/shared-icons/check-mark.png)
Trending now
This is a popular solution!
Step by step
Solved in 2 steps
![Blurred answer](/static/compass_v2/solution-images/blurred-answer.jpg)
![FINANCIAL ACCOUNTING](https://compass-isbn-assets.s3.amazonaws.com/isbn_cover_images/9781259964947/9781259964947_smallCoverImage.jpg)
![Accounting](https://www.bartleby.com/isbn_cover_images/9781337272094/9781337272094_smallCoverImage.gif)
![Accounting Information Systems](https://www.bartleby.com/isbn_cover_images/9781337619202/9781337619202_smallCoverImage.gif)
![FINANCIAL ACCOUNTING](https://compass-isbn-assets.s3.amazonaws.com/isbn_cover_images/9781259964947/9781259964947_smallCoverImage.jpg)
![Accounting](https://www.bartleby.com/isbn_cover_images/9781337272094/9781337272094_smallCoverImage.gif)
![Accounting Information Systems](https://www.bartleby.com/isbn_cover_images/9781337619202/9781337619202_smallCoverImage.gif)
![Horngren's Cost Accounting: A Managerial Emphasis…](https://www.bartleby.com/isbn_cover_images/9780134475585/9780134475585_smallCoverImage.gif)
![Intermediate Accounting](https://www.bartleby.com/isbn_cover_images/9781259722660/9781259722660_smallCoverImage.gif)
![Financial and Managerial Accounting](https://www.bartleby.com/isbn_cover_images/9781259726705/9781259726705_smallCoverImage.gif)